Solid Tumors
Lung Cancer
1
| Disease Status and/or Stage | Non-Small Cell Lung Cancer |
|---|---|
| Protocol Title | CALGB 140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2cm) Peripheral Non-Small Cell Lung Cancer |
| PI | Nasser Altorki, MD |
| Contact | Estella Hernandez, RN 212-746-3328 |
| Key Eligibility | Peripheral lung nodule less than or equal to 2 cm on preoperative CT scan and presumed to be lung cancer. No prior malignancy within 5 years other than non-melanoma skin cancer, superficial bladder cancer, or CIS of the cervix. The tumor location must be suitable for either lobar or sublobar resection (wedge or segment) |
| Treatment Overview | Patients will be randomized to receive a Lobectomy or a Sublobar Resection |
2
| Disease Status and/or Stage | Progressive disease after therapies with curative potential or approval salvage regimen |
|---|---|
| Protocol Title | A Phase I/II, Open-Label, Dose Escalation Study of CDX-1401 in PAtients with Malignancies Known to Express NY-ESO-1 |
| PI | Ellen Chuang, MD |
| Contact | Marta Cobham, RN 212-821-0780 |
3
| Disease Status and/or Stage | Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer |
|---|---|
| Protocol Title | Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology |
| PI | Ronald Scheff, MD |
| Contact | Kristen Petrillo, RN 212-746-5430 |
4
| Disease Status and/or Stage | Stage IIIB/IV or Recurrent, Unresectable Non-Small Cell Lung Cancer |
|---|---|
| Protocol Title | A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients |
| PI | Bryan Schneider, MD |
| Contact | Kristen Petrillo, RN 212-746-5430 |
5
| Disease Status and/or Stage | Metastatic Solid Tumors |
|---|---|
| Protocol Title | A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study |
| PI | Scott Tagawa, MD |
| Contact | Kristen Petrillo, RN 212-746-5430 |
6
| Disease Status and/or Stage | Chemotherapy-Induced Peripheral Neuropathy |
|---|---|
| Protocol Title | CALGB 170601: A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN) |
| PI | Elizabeth Popa, MD |
| Contact | Kristen Petrillo, RN 212-746-5430 |
7
| Disease Status and/or Stage | Chemotherapy-Induced Peripheral Neuropathy |
|---|---|
| Protocol Title | CALGB 170601: A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN) |
| PI | Bryan Schneider, M.D. |
| Contact | Kristen Petrillo, RN 212-746-5430 |
| Last updated: May 26, 2010 |  |
